GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iZafe Group AB (OSTO:IZAFE B) » Definitions » Debt-to-EBITDA

iZafe Group AB (OSTO:IZAFE B) Debt-to-EBITDA : -0.21 (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is iZafe Group AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

iZafe Group AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr1.68 Mil. iZafe Group AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.83 Mil. iZafe Group AB's annualized EBITDA for the quarter that ended in Jun. 2024 was kr-12.11 Mil. iZafe Group AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.21.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for iZafe Group AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:IZAFE B' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.38   Med: -0.21   Max: -0.11
Current: -0.18

During the past 13 years, the highest Debt-to-EBITDA Ratio of iZafe Group AB was -0.11. The lowest was -2.38. And the median was -0.21.

OSTO:IZAFE B's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.34 vs OSTO:IZAFE B: -0.18

iZafe Group AB Debt-to-EBITDA Historical Data

The historical data trend for iZafe Group AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iZafe Group AB Debt-to-EBITDA Chart

iZafe Group AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.65 -0.11 -0.18 -0.21 -0.20

iZafe Group AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.22 -0.20 -0.14 -0.21

Competitive Comparison of iZafe Group AB's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, iZafe Group AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iZafe Group AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where iZafe Group AB's Debt-to-EBITDA falls into.



iZafe Group AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

iZafe Group AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.037 + 1.487) / -12.49
=-0.20

iZafe Group AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.678 + 0.828) / -12.108
=-0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


iZafe Group AB  (OSTO:IZAFE B) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


iZafe Group AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of iZafe Group AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


iZafe Group AB Business Description

Traded in Other Exchanges
N/A
Address
Grev Turegatan 11A, Stockholm, SWE, 114 46
iZafe Group AB is a pure Life-Science company engaged in the development of digital drug dispensing. The company conducts research, development and marketing of digital medical solutions and services for safer drug management at home. iZafe's drug robot Dosell is used to reduce the risk of incorrect medication at home, relieve public care, increase the patient's quality of life and create a safer environment for relatives. The customers consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe sells through well-established partners who already have long and deep customer relationships with the priority customer groups.

iZafe Group AB Headlines

No Headlines